The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...
The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between ...
Stocktwits on MSN
BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company
The clarification from the German biotech company comes on the heels of a Bloomberg report that Pfizer is considering selling ...
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...
Stocktwits on MSN
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report
Pfizer completed the acquisition of Metsera for up to $86.25 per share earlier on Thursday after a bidding war with Danish ...
Britain on Wednesday became the first country in the world to approve the COVID-19 vaccine developed by U.S. drugmaker Pfizer and its German partner BioNTech , , and said it will be rolled out from ...
WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin ...
Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations.
Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback